High-Dose TXA Is Associated with Less Blood Loss Than Low-Dose TXA without Increased Complications in Patients with Complex Adult Spinal Deformity
Andrew H Kim,Kevin C Mo,Andrew B Harris,Renaud Lafage,Brian J Neuman,Richard A Hostin,Alexandra Soroceanu,Han Jo Kim,Eric O Klineberg,Jeffrey L Gum,Munish C Gupta,D Kojo Hamilton,Frank Schwab,Doug Burton,Alan Daniels,Peter G Passias,Robert A Hart,Breton G Line,Christopher Ames,Virginie Lafage,Christopher I Shaffrey,Justin S Smith,Shay Bess,Lawrence Lenke,Khaled M Kebaish,International Spine Study Group,Behrooz Akbarnia,Neel Anand,Oheneba Boachie-Adjei,Keith Bridwell,Douglas Burton,Dean Chou,Matthew E Cunningham,Vedat Deviren,Robert Eastlack,Richard Fessler,Steven Glassman,Jeffrey Gum,Munish Gupta,Robert Hart,Naobumi Hosogane,Richard Hostin,Yashar Javidan,Kai Ming Fu,Adam Kanter,Khaled Kebaish,Michael Kelly,Eric Klineberg,Breton Line,Praveen Mummaneni,Gregory Mundis,Brian Neuman,Pierce Nunley,David Okonkwo,Paul Park,Peter Passias,Themistocles Protopsaltis,Justin Scheer,Daniel Sciubba,Christopher Shaffrey,Tamir Ailon,Khoi Than,Juan Uribe,Michael Wang,Mitsuru Yagi,Samrat Yeramaneni
DOI: https://doi.org/10.2106/JBJS.23.01323
2024-10-03
Abstract:Background: Tranexamic acid (TXA) is commonly utilized to reduce blood loss in adult spinal deformity (ASD) surgery. Despite its widespread use, there is a lack of consensus regarding the optimal dosing regimen. The aim of this study was to assess differences in blood loss and complications between high, medium, and low-dose TXA regimens among patients undergoing surgery for complex ASD. Methods: A multicenter database was retrospectively analyzed to identify 265 patients with complex ASD. Patients were separated into 3 groups by TXA regimen: (1) low dose (<20-mg/kg loading dose with ≤2-mg/kg/hr maintenance dose), (2) medium dose (20 to 50-mg/kg loading dose with 2 to 5-mg/kg/hr maintenance dose), and (3) high dose (>50-mg/kg loading dose with ≥5-mg/kg/hr maintenance dose). The measured outcomes included blood loss, complications, and red blood cell (RBC) units transfused intraoperatively and perioperatively. The multivariable analysis controlled for TXA dosing regimen, levels fused, operating room time, preoperative hemoglobin, 3-column osteotomy, and posterior interbody fusion. Results: The cohort was predominantly White (91.3%) and female (69.1%) and had a mean age of 61.6 years. Of the 265 patients, 54 (20.4%) received low-dose, 131 (49.4%) received medium-dose, and 80 (30.2%) received high-dose TXA. The median blood loss was 1,200 mL (interquartile range [IQR], 750 to 2,000). The median RBC units transfused intraoperatively was 1.0 (IQR, 0.0 to 2.0), and the median RBC units transfused perioperatively was 2.0 (IQR, 1.0 to 4.0). Compared with the high-dose group, the low-dose group had increased blood loss (by 513.0 mL; p = 0.022) as well as increased RBC units transfused intraoperatively (by 0.6 units; p < 0.001) and perioperatively (by 0.3 units; p = 0.024). The medium-dose group had increased blood loss (by 491.8 mL; p = 0.006) as well as increased RBC units transfused intraoperatively (by 0.7 units; p < 0.001) and perioperatively (by 0.5 units; p < 0.001) compared with the high-dose group. Conclusions: Patients with ASD who received high-dose intraoperative TXA had fewer RBC transfusions intraoperatively, fewer RBC transfusions perioperatively, and less blood loss than those who received low or medium-dose TXA, with no differences in the rates of seizure or thromboembolic complications. Level of evidence: Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.